# US 2008/0076782 A1 · Sodium channel blockers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076782 A1
- Document ID: US20080076782A1
- Status: Published application
- Kind: A1
- Application number: 11/950,674
- Filed: 2007-12-05
- Published: 2008-03-27
- Earliest claimed: 2003-02-19
- Assignees: Parion Sciences, Inc.
- Inventors: Michael JOHNSON
- Web page: https://patentgrep.com/patent/US20080076782A1

## CPC

- A61K 31/4965: Non-condensed pyrazines
- A61K 31/497: containing further heterocyclic rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/10: Laxatives
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 15/02: for disorders of the vagina
- A61P 17/00: Drugs for dermatological disorders
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 241/26: with nitrogen atoms directly attached to ring carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

## Claims

### Claim 1

(canceled)

### Claim 2

A method of increasing hydration of a mucosal surface of a subject, comprising topically administering to a mucosal surface of a subject an effective amount of pyrazinoylguanidine compound represented by formula (I):
wherein
X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;
Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or —N(R2)2;
R1 is hydrogen or lower alkyl;
each R2 is, independently, —R7, —(CH2)m—OR8, —(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(═O)NR7R10, —(CH2)n-Zg-R7, —(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, or
wherein when two —CH2OR8 groups are located 1,2- or 1,3- with respect to each other the R8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
R3 and R4 are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl, phenyl-lower alkyl, (halophenyl)-lower alkyl, lower-(alkylphenylalkyl), lower (alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or pyridyl-lower alkyl, with the proviso that at least one of R3 and R4 is a group represented by formula (A):
wherein
each RL is, independently, —R7, —(CH2)n—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —O—(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(═O)NR7R10, —O—(CH2)m—C(═O)NR7R10, —(CH2)n-(Z)g-R7, —O—(CH2)m-(Z)g-R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, —O—(CH2)m—CO2R7—OSO3H, —O-glucuronide, —O-glucose,
wherein when two —CH2OR8 groups are located 1,2- or 1,3- with respect to each other the R8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
each o is, independently, an integer from 0 to 10;
each p is an integer from 0 to 10;
with the proviso that the sum of o and p in each contiguous chain is from 1 to 10;
each x is, independently, O, NR10, C(═O), CHOH, C(═N—R10), CHNR7R10, or represents a single bond;
each R5 is, independently, —(CH2)n—NR12R12, —O—(CH2)m—NR12R12, —O—(CH2)n—NR12R12, —O—(CH2)m-(Z)gR12, —(CH2)nNR11R11, —O—(CH2)mNR11R11, —(CH2)n—N⊕—(R11)3, —O—(CH2)m—N⊕—(R11)3, —(CH2)n-(Z)g-(CH2)m—NR10R10, —O—(CH2)m-(Z)g-(CH2)m—NR10R10, —(CH2CH2O)m—CH2CH2NR12R12, —O—(CH2CH2O)m—CH2CH2NR12R12, —(CH2)n—(C═O)NR12R12, —O—(CH2)m—(C═O)NR12R12, —O—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10, —(CH2)n—(CHOR8)mCH2—NR10-(Z)g-R10, —(CH2)nNR10—O(CH2)m(CHOR8)nCH2NR10-(Z)g-R10, —O(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10, -(Het)-(CH2)m—OR8, -(Het)-(CH2)m—NR7R10, -(Het)-(CH2)m(CHOR8)(CHOR8)n—CH2OR8, -(Het)-(CH2CH2O)m—R8, -(Het)-(CH2CH2O)m—CH2CH2NR7R10, -(Het)-(CH2)m—C(═O)NR7R10, -(Het)-(CH2)m-(Z)g-R7, -(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, -(Het)-(CH2)m—CO2R7, -(Het)-(CH2)m—NR12R12, -(Het)-(CH2)n—NR12R12, -(Het)-(CH2)m-(Z)gR12, -(Het)-(CH2)mNR11R11, —(Het)-(CH2)m—N⊕—(R11)3, -(Het)-(CH2)m-(Z)g-(CH2)m—NR10R10, -(Het)-(CH2CH2O)m—CH2CH2NR12R12, -(Het)-(CH2)m—(C═O)NR12R12, -(Het)-(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10, -(Het)-(CH2)m—NR10—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10, wherein when two —CH2OR8 groups are located 1,2- or 1,3- with respect to each other the R8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—(CH2)n(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located adjacent to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located adjacent to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located adjacent to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located adjacent to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
each R6 is, independently, —R5, —R7, —OR8, —N(R7)2, —(CH2)m—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —O—(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(═O)NR7R10, —O—(CH2)m—C(═O)NR7R10, —(CH2)n-(Z)g-R7, —O—(CH2)m-(Z)g-R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2), —CO2R7, —O—(CH2)m—CO2R7, —OSO3H, —O-glucuronide, —O-glucose,
wherein when two R6 are —OR11 and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two R6 may be bonded together to form a methylenedioxy group, and
wherein when two —CH2OR8 groups are located 1,2- or 1,3- with respect to each other the R8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
each R7 is, independently, hydrogen or lower alkyl;
each R8 is, independently, hydrogen, lower alkyl, —C(═O)—R11, glucuronide, 2-tetrahydropyranyl, or
each R9 is, independently, —CO2R7, —CON(R7)2, —SO2CH3, or —C(═O)R7;
each R10 is, independently, —H, —SO2CH3, —CO2R7, —C(═O)NR7R9, —C(═O)R7, or —CH2—(CHOH)n—CH2OH;
each Z is, independently, CHOH, C(═O), CHNR7R10, C═NR10, or NR10;
each R11 is, independently, lower alkyl;
each R12 is independently, —SO2CH3, —CO2R7, —C(═O)NR7R9, —C(═O)R7, or —CH2—(CHOH)n—CH2OH;
each Het is independently, —NR7, —NR10, —S—, —SO—, or —SO2—;
each g is, independently, an integer from 1 to 6;
each m is, independently, an integer from 1 to 7;
each n is, independently, an integer from 0 to 7;
each Q is, independently, C—R5, C—R6, or a nitrogen atom, wherein one, two or three Q in a ring are nitrogen atoms;
or a pharmaceutically acceptable salt thereof, and
inclusive of all enantiomers, diastereomers, and racemic mixtures thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein Y is NH2, X is Cl, each R2, R1, R3, RL, and R6 is H, o is 4, p is 0, and x is a single bond.

### Claim 4 (depends on 3)

The method of claim 3, wherein R5 is
—(CH2)n—NR12R12,
—(CH2)n—N(SO2R7)2,
—(CH2)nNR11R11,
—O—(CH2)m—NR12R12,
—O—(CH2)m—N(SO2R7)2,
—O—(CH2)m-(Z)gR12,
—(CH2)n—CHNHBocCO2R7 (α),
—O—(CH2)m—CHNHBocCO2R7 (α),
—(CH2)n—N(R11)2,
—O—(CH2)m—N(R11)2,
—(CH2)n—CHNH2CO2R7 (α),
—O—(CH2)m—CHNH2CO2R7 (α),
—O—(CH2)m—N+(R11)3,
—(CH2)n-(Z)g-(CH2)m—NR10R10,
—C(═O)NH—(CH2)m—N(R10)2,
—NHC(═O)(CH2)m—N(R10)2,
—C(═O)NH—(CH2)m—NH—C(═NH)—N(R7)2,
—NH—C(═O)—(CH2)mNH—C(═NH)—N(R10)2,
—O—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
—(CH2)n—(CHOR8)mCH2—NR10-(Z)g-R10,
—(CH2)nNR10—(CH2)m(CHOR8)nCH2NR10-(Z)g-R10,
—O(CH2)m—NR10—(CH2)m—(CHOH8)nCH2NR10-(Z)g-R10,
—(CH2CH2O)m—CH2CH2NR12R12,
—O—(CH2CH2O)m—CH2CH2NR12R12,
—(CH2)n—(C═O)NR12R12,
—O—(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—OR8,
-(Het)-(CH2)m—NR7R10,
-(Het)-(CH2)2-7(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2CH2O)m—R8,
-(Het)-(CH2CH2O)m—CH2CH2NR7R10,
-(Het)-(CH2)m—C(═O)NR7R10,
-(Het)-(CH2)m-(Z)g-R7,
-(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2)m—CO2R7,
-(Het)-(CH2)m—NR12R12,
-(Het)-(CH2)n—NR12R12,
-(Het)-(CH2)m-(Z)gR12,
-(Het)-(CH2)mNR12R12,
-(Het)-(CH2)m—N⊕—(R11)3,
-(Het)-(CH2CH2O)m—CH2CH2NR12R12,
-(Het)-(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
-(Het)-(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10,
—(CH2)n(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane.

### Claim 5 (depends on 2)

The method of claim 2, wherein one Q in a ring is a nitrogen atom.

### Claim 6 (depends on 5)

The method of claim 5, wherein Y is NH2, X is Cl, each R2, R1, R3, RL, and R6 is H, o is 4, p is 0, and x is a single bond.

### Claim 7 (depends on 6)

The method of claim 6, wherein R5 is
—(CH2)n—NR12R12,
—(CH2)n—N(SO2R7)2,
—(CH2)nNR11R11,
—O—(CH2)m—N12R12,
—O—(CH2)m—N(SO2R7)2,
—O—(CH2)m-(Z)gR12,
—(CH2)n—CHNHBocCO2R7 (α),
—O—(CH2)m—CHNHBocCO2R7 (α),
—(CH2)n—N(R11)2,
—O—(CH2)m—N(R11)2,
—(CH2)n—CHNH2CO2R7 (α),
—O—(CH2)m—CHNH2CO2R7 (α),
—O—(CH2)m—N+(R11)3,
—(CH2)n-(Z)g-(CH2)m—NR10R10,
—C(═O)NH—(CH2)m—N(R10)2,
—NHC(═O)(CH2)m—N(R10)2,
—C(═O)NH—(CH2)m—NH—C(═NH)—N(R7)2,
—NH—C(═O)—(CH2)mNH—C(═NH)—N(R10)2,
—O—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
—(CH2)n—(CHOR8)mCH2—NR10-(Z)g-R10, —(CH2)nNR10—(CH2)m(CHOR8)nCH2NR10-(Z)g-R10,
—O(CH2)m—NR10—(CH2)m—(CHOH8)nCH2NR10-(Z)g-R10,
—(CH2CH2O)m—CH2CH2NR12R12,
—O—(CH2CH2O)m—CH2CH2NR12R12,
—(CH2)n—(C═O)NR12R12,
—O—(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—OR8,
-(Het)-(CH2)m—NR7R10,
-(Het)-(CH2)2-7(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2CH2O)m—R8,
-(Het)-(CH2CH2O)m—CH2CH2NR7R10,
-(Het)-(CH2)m—C(═O)NR7R10,
-(Het)-(CH2)m-(Z)g-R7,
-(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2)m—CO2R7,
-(Het)-(CH2)m—NR12R12,
-(Het)-(CH2)n—NR12R12,
-(Het)-(CH2)m-(Z)gR12,
-(Het)-(CH2)mNR11R11,
-(Het)-(CH2)m—N⊕—(R11)3,
-(Het)-(CH2CH2O)m—CH2CH2NR12R12,
-(Het)-(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
-(Het)-(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10,
—(CH2)n(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
(CH2), —NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane.

### Claim 8 (depends on 2)

The method of claim 2, wherein two Q in a ring is a nitrogen atom.

### Claim 9 (depends on 8)

The method of claim 8, wherein Y is NH2, X is Cl, each R2, R1, R3, RL, and R6 is H, o is 4, p is O, and x is a single bond.

### Claim 10 (depends on 9)

The method of claim 9, wherein R5 is
—(CH2)n—NR12R12,
—(CH2)n—N(SO2R7)2,
—(CH2)nNR11R11,
—O—(CH2)m—NR12R12,
—O—(CH2)m—N(SO2R7)2,
—O—(CH2)m-(Z)gR12,
—(CH2)n—CHNHBocCO2R7 (α),
—O—(CH2)m—CHNHBocCO2R7 (α),
—(CH2)n—N(R11)2,
—O—(CH2)m—N(R11)2,
—(CH2)n—CHNH2CO2R7 (α),
—O—(CH2)m—CHNH2CO2R7 (α),
—O—(CH2)m—N+(R11)3,
—(CH2)n-(Z)g-(CH2)m—NR10R10,
—C(═O)NH—(CH2)m—N(R10)2,
—NHC(═O)(CH2)m—N(R10)2,
—C(═O)NH—(CH2)m—NH—C(═NH)—N(R7)2,
—NH—C(═O)—(CH2)mNH—C(═NH)—N(R10)2,
—O—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
—(CH2)n—(CHOR8)mCH2—NR10-(Z)g-R10,
—(CH2)nNR10—(CH2)m(CHOR8)nCH2NR10-(Z)g-R10,
—O(CH2)m—NR10—(CH2)m—(CHOH8)nCH2NR10-(Z)g-R10,
—(CH2CH2O)m—CH2CH2NR12R12,
—O—(CH2CH2O)m—CH2CH2NR12R12,
—(CH2), —(C═O)NR12R12,
—O—(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—OR8,
-(Het)-(CH2)m—NR7R10,
-(Het)-(CH2)2-7(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2CH2O)m—R8,
-(Het)-(CH2CH2O)m—CH2CH2NR7R10,
-(Het)-(CH2)m—C(═O)NR7R10,
-(Het)-(CH2)m-(Z)g-R7,
-(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2)m—CO2R7,
-(Het)-(CH2)m—NR12R12,
-(Het)-(CH2)n—NR12R12,
-(Het)-(CH2)m-(Z)gR12,
-(Het)-(CH2)mNR11R11,
-(Het)-(CH2)m—N⊕—(R11)3,
-(Het)-(CH2CH2O)m—CH2CH2NR12R12,
-(Het)-(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—(CHOR8)mCH2N10-(Z)g-R10,
-(Het)-(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10,
—(CH2)n(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane.

### Claim 11 (depends on 10)

The method of claim 10, wherein three Q in a ring is a nitrogen atom.

### Claim 12 (depends on 11)

The method of claim 11, wherein Y is NH2, X is Cl, each R2, R1, R3, RL, and R6 is H, o is 4, p is 0, and x is a single bond.

### Claim 13 (depends on 12)

The method of claim 12, wherein R5 is
—(CH2)n—NR12R12,
—(CH2)n—N(SO2R7)2,
—(CH2)nNR11R11,
—O—(CH2)m—NR12R12,
—O—(CH2)m—N(SO2R7)2,
—O—(CH2)m-(Z)gR12,
—(CH2)n—CHNHBocCO2R7 (α),
—O—(CH2)m—CHNHBocCO2R7 (α),
—(CH2)n—N(R11)2,
—O—(CH2)m—N(R11)2,
—(CH2)n—CHNH2CO2R7 (α),
—O—(CH2)m—CHNH2CO2R7 (α),
—O—(CH2)m—N+(R11)3,
—(CH2)n-(Z)g-(CH2)m—NR10R10,
—C(═O)NH—(CH2)m—N(R10)2,
—NHC(═O)(CH2)m—N(R10)2,
—C(═O)NH—(CH2)m—NH—C(═NH)—N(R7)2,
—NH—C(═O)—(CH2)mNH—C(═NH)—N(R10)2,
—O—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
—(CH2)n—(CHOR8)mCH2—N10-(Z)g-R10,
—(CH2)nNR10—(CH2)m(CHOR8)nCH2NR10-(Z)g-R10,
—O(CH2)m—NR10—(CH2)m—(CHOH8)nCH2NR10-(Z)g-R10,
—(CH2CH2O)m—CH2CH2NR12R12,
—O—(CH2CH2O)m—CH2CH2NR12R12,
—(CH2)n—(C═O)NR12R12,
—O—(CH2)m—(C═O)NR12R12,
-(Het)-(CH2), —OR8,
-(Het)-(CH2)m—NR7R10,
-(Het)-(CH2)2-7(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2CH2O)m—R8,
-(Het)-(CH2CH2O)m—CH2CH2NR7R10,
-(Het)-(CH2)m—C(═O)NR7R10,
-(Het)-(CH2)m-(Z)g-R7,
-(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2)m—CO2R7,
-(Het)-(CH2)m—NR12R12,
-(Het)-(CH2)—NR12R12,
-(Het)-(CH2)m-(Z)gR12,
-(Het)-(CH2)mNR11R11,
-(Het)-(CH2)m—N⊕—(R11)3,
-(Het)-(CH2CH2O)m—CH2CH2NR12R12,
-(Het)-(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
-(Het)-(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10,
—(CH2)n(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R3 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane.

### Claim 14

A method of promoting hydration of a mucosal surface, comprising topically administering to a mucosal surface of a subject a pyrazinoylguanidine compound represented by formula (I):
wherein
X is hydrogen, halogen, trifluoromethyl, lower alkyl, unsubstituted or substituted phenyl, lower alkyl-thio, phenyl-lower alkyl-thio, lower alkyl-sulfonyl, or phenyl-lower alkyl-sulfonyl;
Y is hydrogen, hydroxyl, mercapto, lower alkoxy, lower alkyl-thio, halogen, lower alkyl, unsubstituted or substituted mononuclear aryl, or —N(R2)2;
R1 is hydrogen or lower alkyl;
each R2 is, independently, —R7, —(CH2)m—OR8, —(CH2)m—N7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(═O)NR7R10, —(CH2)n-Zg-R7, —(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, or
wherein when two —CH2OR8 groups are located 1,2- or 1,3- with respect to each other the R8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
R3 and R4 are each, independently, hydrogen, a group represented by formula (A), lower alkyl, hydroxy lower alkyl, phenyl, phenyl-lower alkyl, (halophenyl)-lower alkyl, lower-(alkylphenylalkyl), lower (alkoxyphenyl)-lower alkyl, naphthyl-lower alkyl, or pyridyl-lower alkyl, with the proviso that at least one of R3 and R4 is a group represented by formula (A):
wherein
each RL is, independently, —R7, —(CH2)n—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —O—(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)n—C(═O)NR7R10, —O—(CH2)m—C(═O)NR7R10, —(CH2)n-(Z)g-R7, —O—(CH2)-(Z)g-R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)—CO2R7, —O—(CH2)m—CO2R7, —OSO3H, —O-glucuronide, —O-glucose,
wherein when two —CH2OR8 groups are located 1,2- or 1,3- with respect to each other the R8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
each o is, independently, an integer from 0 to 10;
each p is an integer from 0 to 10;
with the proviso that the sum of o and p in each contiguous chain is from 1 to 10;
each x is, independently, O, NR10, C(═O), CHOH, C(═N—R10), CHNR7R10, or represents a single bond;
each R5 is, independently, —(CH2), —NR12R12, —O—(CH2)m—NR12R12, —O—(CH2)n—NR12R12, —O—(CH2)m-(Z)gR12, —(CH2)nNR11R11, —O—(CH2)mNR11R11, —(CH2)n—N⊕—(R11)3, —O—(CH2)m—N⊕(R11)3, —(CH2)n-(Z)g-(CH2)m—NR10R10, —O—(CH2)m-(Z)g-(CH2)m—NR10R10, —(CH2CH2O)m—CH2CH2NR12R12, —O—(CH2CH2O)m—CH2CH2NR12R12, —(CH2)n—(C═O)NR12R12, —O—(CH2)m—(C═O)NR12R12, —O—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10, —(CH2)n—(CHOR8)mCH2—NR10-(Z)g-R10, —(CH2)nNR10—O(CH2)m(CHOR8)nCH2NR10-(Z)g-R10, —O(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10, -(Het)-(CH2)m—OR8, -(Het)-(CH2)m—N7R10, -(Het)-(CH2)m(CHOR8)(CHOR8)n—CH2OR8, -(Het)-(CH2CH2O)m—R8, -(Het)-(CH2CH2O)m—CH2CH2NR7R10, -(Het)-(CH2)m—C(═O)NR7R10, -(Het)-(CH2)m-(Z)g-R7, -(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, -(Het)-(CH2)m—CO2R7, -(Het)-(CH2)m—NR12R12, -(Het)-(CH2)n—NR12R12, -(Het)-(CH2)m-(Z)gR12, -(Het)-(CH2)mNR11R11, -(Het)-(CH2)m—N⊕—(R11)3, -(Het)-(CH2)m-(Z)g-(CH2)m—NR10R10, -(Het)-(CH2CH2O)m—CH2CH2NR12R12, -(Het)-(CH2)m—(C═O)NR12R12, -(Het)-(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10, -(Het)-(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10, wherein when two —CH2OR8 groups are located 1,2- or 1,3- with respect to each other the R8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—(CH2)n(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located adjacent to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located adjacent to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—(CH2)n—N10— —CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located adjacent to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located adjacent to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
each R6 is, independently, —R5, —R7, —OR8, —N(R7)2, —(CH2)m—OR8, —O—(CH2)m—OR8, —(CH2)n—NR7R10, —O—(CH2)m—NR7R10, —(CH2)n(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m(CHOR8)(CHOR8)n—CH2OR8, —(CH2CH2O)m—R8, —O—(CH2CH2O)m—R8, —(CH2CH2O)m—CH2CH2NR7R10, —O—(CH2CH2O)m—CH2CH2NR7R10, —(CH2)m—C(═O)NR7R10, —O—(CH2)m—C(═O)NR7R10, —(CH2)n-(Z)g-R7, —O—(CH2)m-(Z)g-R7, —(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, —(CH2)n—CO2R7, —O—(CH2)m—CO2R7, —OSO3H, —O-glucuronide, —O-glucose,
wherein when two R6 are —OR11 and are located adjacent to each other on a phenyl ring, the alkyl moieties of the two R6 may be bonded together to form a methylenedioxy group, and
wherein when two —CH2OR8 groups are located 1,2- or 1,3- with respect to each other the R8 groups may be joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane;
each R7 is, independently, hydrogen or lower alkyl;
each R8 is, independently, hydrogen, lower alkyl, —C(═O)—R11, glucuronide, 2-tetrahydropyranyl, or
each R9 is, independently, —CO2R7, —CON(R7)2, —SO2CH3, or —C(═O)R7;
each R10 is, independently, —H, —SO2CH3, —CO2R7, —C(═O)NR7R9, —C(═O)R7, or —CH2—(CHOH)n—CH2OH;
each Z is, independently, CHOH, C(═O), CHNR7R10, C═NR10, or NR10;
each R11 is, independently, lower alkyl;
each R12 is independently, —SO2CH3, —CO2R7, —C(═O)NR7R9, —C(═O)R7, or —CH2—(CHOH)n—CH2OH;
each Het is independently, —NR7, —NR10, —S—, —SO—, or —SO2—;
each g is, independently, an integer from 1 to 6;
each m is, independently, an integer from 1 to 7;
each n is, independently, an integer from 0 to 7;
each Q is, independently, C—R5, C—R6, or a nitrogen atom, wherein one, two or three Q in a ring are nitrogen atoms;
or a pharmaceutically acceptable salt thereof, and
inclusive of all enantiomers, diastereomers, and racemic mixtures thereof,
whereby the hydration of the mucosal surface is increased.

### Claim 15 (depends on 14)

The method of claim 14, wherein Y is NH2, X is Cl, each R2, R1, R3, RL, and R6 is H, o is 4, p is 0, and x is a single bond.

### Claim 16 (depends on 15)

The method of claim 15, wherein R5 is
—(CH2)n—NR12R12,
—(CH2)n—N(SO2R7)2,
—(CH2)nNR11R11,
—O—(CH2)m—NR12R12,
—O—(CH2)m—N(SO2R7)2,
—O—(CH2)m-(Z)gR12,
—(CH2)n—CHNHBocCO2R7 (α),
—O—(CH2)m—CHNHBocCO2R7 (α),
—(CH2)n—N(R11)2,
—O—(CH2)m—N(R11)2,
(CH2)n—CHNH2CO2R7 (α),
—O—(CH2)m—CHNH2CO2R7 (α),
—O—(CH2)m—N+(R11)3,
—(CH2)n-(Z)g-(CH2)m—NR10R10,
—C(═O)NH(CH2)m—N(R10)2,
—NHC(═O)(CH2)m—N(R10)2,
—C(═O)NH—(CH2)m—NH—C(═NH)—N(R7)2,
—NH—C(═O)—(CH2)m—NH—C(═NH)—N(R10)2,
—O—(CH2)m—(CHOR8)mCH2N10-(Z)g-R10,
—(CH2)n—(CHOR8)mCH2—NR10-(Z)g-R10,
—(CH2)nNR10—(CH2)m(CHOR8)nCH2NR10-(Z)g-R10,
—O(CH2)m—NR10—(CH2)m—(CHOH8)nCH2NR10-(Z)g-R10,
—(CH2CH2O)m—CH2CH2NR12R12,
—O—(CH2CH2O)m—CH2CH2NR12R12,
—(CH2)m—(C═O)NR12R12,
—O—(CH2)m(C═O)NR12R12,
-(Het)-(CH2)m—OR8,
-(Het)-(CH2)m—NR7R10,
-(Het)-(CH2)2-7(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2CH2O)m—R8,
-(Het)-(CH2CH2O)m—CH2CH2NR7R10,
-(Het)-(CH2)m—C(═O)NR7R10,
-(Het)-(CH2)m-(Z)g-R7,
-(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2)m—CO2R7,
-(Het)-(CH2)m—NR12R12,
-(Het)-(CH2), —NR12R12,
-(Het)-(CH2)m-(Z)gR12,
-(Het)-(CH2)mNR11R11,
-(Het)-(CH2)m—N⊕—(R11)3,
-(Het)-(CH2CH2O)m—CH2CH2NR12R12,
-(Het)-(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
-(Het)-(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10,
—(CH2)n(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane.

### Claim 17 (depends on 14)

The method of claim 14, wherein one Q in a ring is a nitrogen atom.

### Claim 18 (depends on 17)

The method of claim 17, wherein Y is NH2, X is Cl, each R2, R1, R3, RL, and R6 is H, o is 4, p is 0, and x is a single bond.

### Claim 19 (depends on 18)

The method of claim 18, wherein R5 is
—(CH2)n—NR12R12,
—(CH2)n—N(SO2R7)2,
—(CH2)nNR11R11,
—O—(CH2)m—NR12R12,
—O—(CH2)m—N(SO2R7)2,
—O—(CH2)m-(Z)gR12,
—(CH2)n—CHNHBocCO2R7 (α),
—O—(CH2)m—CHNHBocCO2R7 (α),
—(CH2)n—N(R11)2,
—O—(CH2)m—N(R11)2,
—(CH2)n—CHNH2CO2R7 (α),
—O—(CH2)m—CHNH2CO2R7 (α),
—O—(CH2)m—N+(R11)3,
—(CH2)n-(Z)g-(CH2)m—NR10R10,
—C(═O)NH(CH2)m—N(R10)2,
—NHC(═O)(CH2)m—N(R10)2,
—C(═O)NH—(CH2)m—NH—C(═NH)—N(R7)2,
—NH—C(═O)—(CH2)mNH—C(═NH)—N(R10)2,
—O—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
—(CH2)n—(CHOR8)mCH2—NR10-(Z)g-R10,
—(CH2)nNR10—(CH2)m(CHOR8)nCH2NR10-(Z)g-R10,
—O(CH2)m—NR10—(CH2)m—(CHOH8)nCH2NR10-(Z)g-R10,
—(CH2CH2O)m—CH2CH2NR12R12,
—O—(CH2CH2O)mCH2CH2NR12R12,
—(CH2)n—(C═O)NR12R12,
—O—(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—OR8,
-(Het)-(CH2)m—NR7R10,
-(Het)-(CH2)2-7(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2CH2O)m—R8,
-(Het)-(CH2CH2O)m—CH2CH2NR7R10,
-(Het)-(CH2)m—C(═O)NR7R10,
-(Het)-(CH2)m-(Z)g-R7,
-(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2)m—CO2R7,
-(Het)-(CH2)m—NR12R12,
-(Het)-(CH2)n—NR12R12,
-(Het)-(CH2)m-(Z)gR12,
-(Het)-(CH2)mNR11R11,
-(Het)-(CH2)m—N⊕—(R11)3,
-(Het)-(CH2CH2O)m—CH2CH2NR12R12,
-(Het)-(CH12)m—(C═O)NR12R12,
-(Het)-(CH2)—(CHOR8)mCH2NR10-(Z)-R10,
-(Het)-(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10,
(CH2)n(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane.

### Claim 20 (depends on 14)

The method of claim 14, wherein two Q in a ring is a nitrogen atom.

### Claim 21 (depends on 20)

The method of claim 20, wherein Y is NH2, X is Cl, each R2, R1, R3, RL, and R6 is H, o is 4, p is 0, and x is a single bond.

### Claim 22 (depends on 21)

The method of claim 21, wherein R5 is
—(CH2)n—NR12R12,
—(CH2)n—N(SO2R7)2,
—(CH2)nNR11R11,
—O—(CH2)m—NR12R12,
—O—(CH2)m—N(SO2R7)2,
—O—(CH2)m-(Z)gR12,
—(CH2)m—CHNHBocCO2R7 (α),
—O—(CH2)m—CHNHBocCO2R7 (α),
—(CH2)n—N(R11)2,
—O—(CH2)m—N(R11)2,
—(CH2)n—CHNH2CO2R7 (α),
—O—(CH2)m—CHNH2CO2R7 (α),
—O—(CH2)m—N+(R11)3,
—(CH2)n-(Z)g-(CH2)m—NR10R10,
—C(═O)NH—(CH2)m—N(R10)2,
—NHC(═O)(CH2)m—N(R10)2,
—C(═O)NH—(CH2)m—NH—C(═NH)—N(R7)2,
—NH—C(═O)—(CH2)mNH—C(═NH)—N(R10)2,
—O—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
—(CH2)n—(CHOR8)mCH2—NR10-(Z)g-R10,
—(CH2)nNR10—(CH2)m(CHOR8)nCH2NR10-(Z)g-R10,
—O(CH2)m—NR10—(CH2)m—(CHOH8)nCH2NR10-(Z)g-R10,
—(CH2CH2O)m—CH2CH2NR12R12,
—O—(CH2CH2O)m—CH2CH2NR12R12,
—(CH2)n—(C═O)NR12R12,
—O—(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—OR8,
-(Het)-(CH2)m—NR7R10,
-(Het)-(CH2)2-7(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2CH2O)m—R8,
-(Het)-(CH2CH2O)m—CH2CH2NR7R10,
-(Het)-(CH2)m—C(═O)NR7R10,
-(Het)-(CH2)m-(Z)g-R7,
-(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2)m—CO2R7,
-(Het)-(CH2)m—NR12R12,
-(Het)-(CH2)n—NR12R12,
-(Het)-(CH2)m-(Z)gR12,
-(Het)-(CH2)m—NR11R11,
-(Het)-(CH2)m—N⊕—(R11)3,
-(Het)-(CH2CH2O)m—CH2CH2NR12R12,
-(Het)-(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
-(Het)-(CH2)m—NR10—(CH2)m—(CHOR8)nCH2NR10-(Z)g-R10,
(CH2)n(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane.

### Claim 23 (depends on 14)

The method of claim 14, wherein three Q in a ring is a nitrogen atom.

### Claim 24 (depends on 23)

The method of claim 23, wherein Y is NH2, X is Cl, each R2, R1, R3, RL, and R6 is H, o is 4, p is 0, and x is a single bond.

### Claim 25 (depends on 24)

The method of claim 24, wherein R5 is
—(CH2)n—NR12R12,
—(CH2)n—N(SO2R7)2,
—(CH2)nNR11R11,
—O—(CH2)m—NR12R12,
—O—(CH2)m—N(SO2R7)2,
—O—(CH2)m-(Z)gR12,
—(CH2)n—CHNHBocCO2R7 (α),
—O—(CH2)m—CHNHBocCO2R7 (α),
—(CH2)n—N(R11)2,
—O—(CH2)m—N(R11)2,
—(CH2)n—CHNH2CO2R7 (α),
—O—(CH2)m—CHNH2CO2R7 (α),
—O—(CH2)m—N+(R11)3,
—(CH2)n-(Z)g-(CH2)m—NR10R10,
—C(═O)NH—(CH2)m—N(R10)2,
—NHC(═O)(CH2)m—N(R10)2,
—C(═O)NH—(CH2)m—NH—C(═NH)—N(R7)2,
—NH—C(═O)—(CH2)mNH—C(═NH)—N(R10)2,
—O—(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
—(CH2)n—(CHOR8)mCH2—NR10-(Z)g-R10,
—(CH2)nNR10—(CH2)m(CHOR8)nCH2NR10-(Z)g-R10,
—O(CH2)m—NR10—(CH2)m—(CHOH8)nCH2NR10-(Z)g-R10,
—(CH2CH2O)m—CH2CH2NR12R12,
—O—(CH2CH2O)m—CH2CH2NR12R12,
—(CH2)n—(C═O)NR12R12,
—O—(CH2)m—(C═O)NR12R12,
-(Het)-(CH2)m—OR8,
-(Het)-(CH2)m—NR7R10,
-(Het)-(CH2)2-7(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2CH2O)m—R8,
-(Het)-(CH2CH2O)m—CH2CH2NR7R10,
-(Het)-(CH2)m—C(═O)NR7R10,
-(Het)-(CH2)m-(Z)g-R7,
-(Het)-(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8,
-(Het)-(CH2)m—CO2R7,
-(Het)-(CH2)m—NR12R12,
-(Het)-(CH2)n—NR12R12,
-(Het)-(CH2)m-(Z)gR12,
-(Het)-(CH2)mNR11R11,
-(Het)-(CH2)m—N⊕—(R11)3,
-(Het)-(CH2CH2O)m—CH2CH2NR12R12,
-(Het)-(CH2)m—(C═O)R12R12,
-(Het)-(CH2)m—(CHOR8)mCH2NR10-(Z)g-R10,
-(Het)-(CH2)m—NR10—(CH2)—(CHOR8)nCH2NR10-(Z)g-R10,
(CH2)n(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—(CH2)n—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane,
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)n—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane, or
—O—(CH2)m—NR10—CH2(CHOR8)(CHOR8)1-7—CH2OR8, with the proviso that at least two —CH2OR8 are located 1,2- or 1,3- with respect to each other and the R8 groups are joined to form a cyclic mono- or di-substituted 1,3-dioxane or 1,3-dioxolane.
